SCHEMBL4055830

SCHEMBL4055830

CCc1ccc(S(=O)(=O)O)cc1.Cc1nc2ccccc2s1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
RECQL P46063 1/20 0.45
KDM4E B2RXH2 2/20 0.44
TDP1 Q9NUW8 1/20 0.44
MMP9 P14780 1/20 0.43
HSD17B10 Q99714 1/20 0.43
ALDH1A1 P00352 4/20 0.43
LMNA P02545 1/20 0.43
PKM P14618 1/20 0.43
GAA P10253 1/20 0.42
POLB P06746 1/20 0.42
GFER P55789 1/20 0.42
RAB9A P51151 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9098356 0.86 TDP1 (0.54) MAPTMEN1KMT2ACYP1A2CYP3A4
SCHEMBL4050605 0.84 ALDH1A1 (0.49) MAPTCYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL4055826 0.80 SMN1; SMN2 (0.57) MEN1KMT2AKDM4ETDP1ALDH1A1
SCHEMBL29161422 0.79 ALDH1A1 (0.48) MAPTMEN1KMT2AKDM4ETDP1
SCHEMBL9004662 0.79 KDM4E (0.63) MAPTMEN1KMT2ACYP1A2CYP3A4
Alcohol SCHEMBL28124562 0.76 HSD17B10 (0.54) MAPTMEN1KMT2ACYP1A2CYP3A4
SCHEMBL14871610 0.76 ALDH1A1 (0.54) MAPTMEN1KMT2ACYP1A2CYP2C19
SCHEMBL10446679 0.75 SMN1; SMN2 (0.64) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL55837 0.74 SMN1; SMN2 (0.54) MAPTMEN1KMT2ACYP1A2CYP3A4
SCHEMBL1563242 0.74 CA2 (0.61) MAPTMEN1KMT2ATDP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090247579-A1 2-[3H-THIAZOL-2-YLIDINEMETHYL]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE CANCER RESEARCH TECHNOLOGY LIMITED 2009-10-01 US disclosed
EP-2029584-A2 2-[3H-THIAZOL-2-YLIDINEMETHYL]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE Cancer Research Technology Limited (GB) 2009-03-04 EP disclosed
WO-2007096618-A2 2-[3H-THIAZOL-2-YLIDINEMETHYL]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2007-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247579-A1 2-[3H-THIAZOL-2-YLIDINEMETHYL]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE RB1, RBBP5, RRM2B MAPT 4065/4885MEN1 2905/4885KMT2A 531/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.